Immune responses to multiple antigen peptides containing T and B epitopes from plasmodium falciparum circumsporozoite protein of Brazilian individuals naturally exposed to malaria

Parasite Immunology

Volumn 23, Issue 2, 2001, Pages 103-108

  Avila, Sandra L M ^a   Goldberg, Anna Carla ^a   Arruk, Viviana G ^a   Marin, Maria Lúcia ^a   Guilherme, Luiza ^a   Kalil, Jorge ^a   Ferreira, Antonio Walter ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

B cell epitope; Circumsporozoite protein; HLA; Malaria; Multiple antigen peptides; T cell epitope

Indexed keywords

CIRCUMSPOROZOITE PROTEIN; EPITOPE; HLA ANTIGEN CLASS 2; IMMUNOGLOBULIN G; MALARIA VACCINE; PARASITE ANTIGEN; PEPTIDE; PROTOZOAL PROTEIN; UNCLASSIFIED DRUG;

ANTIBODY DETECTION; ANTIBODY RESPONSE; ARTICLE; B LYMPHOCYTE; BRAZIL; CELLULAR IMMUNITY; CONTROLLED STUDY; ENDEMIC DISEASE; HAPLOTYPE; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; MALARIA; PARASITE IMMUNITY; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; T LYMPHOCYTE;

PLASMODIUM FALCIPARUM;

EID: 0035088184     PISSN: 01419838     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-3024.2001.00363.x     Document Type: Article

References (23)

1. Cloned cytotoxic T cells recognize an epitope in the circumsporozoite protein and protect against malaria
2. Gamma-interferon, CD81 T cells and antibodies required for immunity to malaria sporozoites
3. Rationale for development of a synthetic vaccine against Plasmodium falciparum malaria
4. Conserved repetitive epitope recognized by CD4 clones from a malaria-immunized volunteer
5. Synthetic peptide vaccine design. Synthesis and properties of a high-density multiple antigenic peptide system
6. Fine specificity of immune responses to epitopic sequences in synthetic peptides containing B and T epitopes from the conserved Plasmodium falciparum blood-stage antigens
7. Multiple antigen peptide. A novel approach to increase detection sensitivity of synthetic peptides in soli-phase immunoassays
8. Peptide-induced memory (IgG) response, cross-reactive with native proteins, requires covalent linkage of a specific B cell epitope with a T cell epitope
9. Immunogenicity of multiple antigen peptides (MAP) containing T and B cell epitopes of the repeat region of the P. falciparum circumsporozoite protein
10. Immunogenicity of an alum-adsorbed synthetic multiple-antigen peptide based on Band T-cell epitopes of the Plasmodium falciparum protein: Possible vaccine application
11. Immunogenicity of multiple antuigen petides containing B and non-repeat T cell epitopes of the circumsporozoite protein of Plasmodium falciparum
12. Standardization of procedures of Plasmodium falciparum antigen preparation for serologic tests
13. DR 'low-resolution' PCR-SSP typing: A correction and an up-date
14. 12th IHWC HLA Class II Reference Protocol
15. Induction of protective immune responses by immunization with linear multiepitope peptides based on conserved sequences from Plasmodium falciparum antigens
16. Immunogenicitiy of Plasmodium falciparum circumsporozoite protein multiple antigen peptide vaccina formulated with different adjuvants
17. Linear and multiple antigen peptides containing defined T and B epitopes of the Plasmodium yoelii circumsporozoite protein: Antibody-mediated protection and boosting by sporozoite infection
18. The use of multiple antigen peptides in the analysis and induction of protective immune responses against infectious diseases
19. Preclinical evaluation of a synthetic Plasmodium falciparum MAP malaria vaccine in Aotus monkeys and mice
20. Binding of malaria T cell epitopes to DR and DQ molecules in vitro correlates with immunogenicity in vivo. Identification of a universal T cell epitope in the Plasmodium falciparum circumsporozoite protein
21. A synthetic vaccine protects humans against challenge with asexual blood stages of Plasmodium falciparum malaria
22. Immunogenicity of chimeric multiple antigen peptides based on Plasmodium falci-parum antigens: Impact of epitope orientation
23. Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria